Shares of Cue Biopharma (CUE) skyrocketed when the company announced that is will provide a business update for shareholders of CUE stock.
Cue Biopharma is a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT.
Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, including discussing the confirmed partial response (PR) recently reported in one patient receiving CUE-101 as second-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
Management will also provide an update on the Company’s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.
In addition to this announcement, the company is scheduled to present at the 2021 Frontiers in Cancer Immunotherapy Conference. The presentation is being held virtually from May 12-14, 2021. The presentation will highlight clinical and preclinical data supporting the mechanism of action (MOA) for the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, its expanding pipeline, and platform derivatives Neo-STAT™ and RDI-STAT™ (Re-Directed Immuno-STATs) to enhance anti-tumor immune responses.
Dr. Quayle will discuss how the Immuno-STAT platform and biologics enable selective engagement of tumor-specific T cell repertoires against tumors.
He will showcase lead drug candidate, CUE-101, derived from the interleukin 2 (IL-2)-based CUE-100 series of Immuno-STATs that are designed for selective delivery of IL-2 to tumor-specific T cells. CUE-101 has shown favorable signs of tolerability, dose-dependent pharmacokinetic (PK) and pharmacodynamic (PD) activity, and anti-tumor activity in an ongoing Phase 1 monotherapy clinical trial for heavily pretreated patients with HPV+ head and neck squamous cell carcinoma.
The presentation will also feature the Company’s second drug candidate, CUE-102, which targets the Wilms tumor (WT1) protein and is expected to reach the clinic in 2022, as well as next-generation platforms, Neo-STAT and RDI-STAT, engineered to address tumor heterogeneity and circumvent tumor escape mechanisms, respectively.